INmune Bio Inc. (INMB)
Develops experimental drugs that reprogram the immune system to fight cancer and inflammatory diseases.
$1.71-0.01%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago-33.2%
The outlook
INMB is trading at $1.71, positioned in the lower third of its 52-week range and above both its 50- and 200-day moving averages. Analyst consensus is Strong Buy with an average price target implying significant upside from current levels. The stock shows a bullish technical setup, though it remains a microcap with limited analyst coverage.
What’s behind the score
Analyst consensusStrong Buy — 1.3 avg of 4 analysts
Price trendAbove its 50- & 200-day averages
52-week range30% of the way from its 52-week low to high
Price targetAvg target +309% vs current price
Analyst price target
~12-month · 4 analysts$7.00average target+309.4% vs now
Now $1.71
Low $4.00High $9.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$45.5M
52-wk high
$3.19
52-wk low
$1.09
50-day avg
$1.55
200-day avg
$1.55
Trailing P/E
—